FDA NDA · NDA212608

AYVAKIT

Sponsor: BLUEPRINT MEDICINES

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
NDA212608
TYPE
NDA
ORIGINAL APPROVAL
2020-01-09
LATEST ACTION
2026-10-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AYVAKIT · ReferencePrescription
AVAPRITINIB 50MG · TABLET · ORAL
AYVAKIT · ReferencePrescription
AVAPRITINIB 300MG · TABLET · ORAL
AYVAKIT · ReferencePrescription
AVAPRITINIB 100MG · TABLET · ORAL
AYVAKIT · ReferencePrescription
AVAPRITINIB 25MG · TABLET · ORAL
AYVAKIT · ReferencePrescription
AVAPRITINIB 200MG · TABLET · ORAL

Approval history

2026-10-16Efficacy · Supplement 21 · standard — Label ↗AP
2024-11-08Labeling · Supplement 20 · standard — Label ↗AP
2023-05-22Efficacy · Supplement 13 · priority — Label ↗AP
2023-03-09Labeling · Supplement 12 · standard — Letter ↗AP
2021-06-16Efficacy · Supplement 6 · priority — Label ↗AP
2021-06-16Efficacy · Supplement 7 · priority — Label ↗AP
2020-01-09Type 1 - New Molecular Entity · Original · priority — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →